The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Targeting deposits in amyloidosis
Ashutosh Wechalekar
• 5 May 2020
Ashutosh Wechalekar, MBBS, FRCP, FRCPath, University College London Hospitals NHS Trust, London, UK, touches on future approaches for amyloidosis treatment, including targeting amyloid deposits with monoclonal antibodies as well as novel therapies targeting amyloidosis precursor proteins. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).
